Zobrazeno 1 - 10
of 204
pro vyhledávání: '"Michael B. Maris"'
Autor:
Jason P. Cooper, Barry E. Storer, Noa Granot, Boglark Gyurkocza, Mohamed L. Sorror, Thomas R. Chauncey, Judith Shizuru, Georg-Nikolaus Franke, Michael B. Maris, Michael Boyer, Benedetto Bruno, Firoozeh Sahebi, Amelia A. Langston, Parameswaran Hari, Edward D. Agura, Søren Lykke Petersen, Richard T. Maziarz, Wolfgang Bethge, Julie Asch, Jonathan A. Gutman, Gitte Olesen, Andrew M. Yeager, Kai Hübel, William J. Hogan, David G. Maloney, Marco Mielcarek, Paul J. Martin, Mary E.D. Flowers, George E. Georges, Ann E. Woolfrey, H. Joachim Deeg, Bart L. Scott, George B. McDonald, Rainer Storb, Brenda M. Sandmaier
Publikováno v:
Haematologica, Vol 106, Iss 6 (2020)
We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, o
Externí odkaz:
https://doaj.org/article/b53a5c54d0c946cb9309c9ef5ead75fa
Autor:
Jeffrey E. Lancet, Gail J. Roboz, Larry D. Cripe, Glenn C. Michelson, Judith A. Fox, Richard D. Leavitt, Tianling Chen, Rachael Hawtin, Adam R. Craig, Farhad Ravandi, Michael B. Maris, Robert K. Stuart, Judith E. Karp
Publikováno v:
Haematologica, Vol 100, Iss 2 (2015)
Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. This study assessed the safety and tolerability of vosaroxin plus cytarabine in patients with relapsed/refractory acute myeloid leukemi
Externí odkaz:
https://doaj.org/article/93594ff6a8384901885ba68dd0e85326
Autor:
Brian Kornblit, David G. Maloney, Barry E. Storer, Michael B. Maris, Lars Vindeløv, Parameswaran Hari, Amelia A. Langston, Michael A. Pulsipher, Wolfgang A. Bethge, Thomas R. Chauncey, Thoralf Lange, Finn B. Petersen, Kai Hübel, Ann E. Woolfrey, Mary E.D. Flowers, Rainer Storb, Brenda M. Sandmaier
Publikováno v:
Haematologica, Vol 99, Iss 10 (2014)
The study is a randomized phase II trial investigating graft-versus-host disease prophylaxis after non-myeloablative (90 mg/m2 fludarabine and 2 Gy total body irradiation) human leukocyte antigen matched unrelated donor transplantation. Patients were
Externí odkaz:
https://doaj.org/article/4630ecb9e33440a8b20dbb5b6ee1c9c9
Autor:
Ron Ram, Rainer Storb, Brenda M. Sandmaier, David G. Maloney, Ann Woolfrey, Mary E. D. Flowers, Michael B. Maris, Ginna G. Laport, Thomas R. Chauncey, Thoralf Lange, Amelia A. Langston, Barry Storer, George E. Georges
Publikováno v:
Haematologica, Vol 96, Iss 8 (2011)
Background Allogeneic hematopoietic cell transplantation is a potentially curative treatment for patients with acute lymphoblastic leukemia. However, the majority of older adults with acute lymphoblastic leukemia are not candidates for myeloablative
Externí odkaz:
https://doaj.org/article/414ae3719d714d29ae3d998ebc01f5b7
Autor:
Kristie A. Blum, Jeffrey G. Supko, Michael B. Maris, Ian W. Flinn, Andre Goy, Anas Younes, Suresh Bobba, Adrian M. Senderowicz, Sergey Efuni, Ronda Rippley, Gozde Colak, Patrick Trojer, Jeremy S. Abramson
Publikováno v:
Cancer Research Communications. 2:795-805
Purpose: NF-κB, a transcription factor essential for inflammatory responses, is constitutively activated in many lymphomas. In preclinical studies, pelabresib (CPI-0610), an investigational (BET) bromodomain inhibitor, downregulated NF-κB signaling
Autor:
Jeremy S. Abramson, Patrick Trojer, Gozde Colak, Ronda Rippley, Sergey Efuni, Adrian M. Senderowicz, Suresh Bobba, Anas Younes, Andre Goy, Ian W. Flinn, Michael B. Maris, Jeffrey G. Supko, Kristie A. Blum
Supplemental tables with the number of patients treated with number of cycles and the incidence of DLTs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3176bc8262bc52b8823efce4e47f6acd
https://doi.org/10.1158/2767-9764.22544999
https://doi.org/10.1158/2767-9764.22544999
Autor:
Jeremy S. Abramson, Patrick Trojer, Gozde Colak, Ronda Rippley, Sergey Efuni, Adrian M. Senderowicz, Suresh Bobba, Anas Younes, Andre Goy, Ian W. Flinn, Michael B. Maris, Jeffrey G. Supko, Kristie A. Blum
Purpose:NF-κB, a transcription factor essential for inflammatory responses, is constitutively activated in many lymphomas. In preclinical studies, pelabresib (CPI-0610), an investigational (BET) bromodomain inhibitor, downregulated NF-κB signaling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19ca73113538578549d12f5fbd38f10c
https://doi.org/10.1158/2767-9764.c.6550823
https://doi.org/10.1158/2767-9764.c.6550823
Autor:
Jeremy S. Abramson, Patrick Trojer, Gozde Colak, Ronda Rippley, Sergey Efuni, Adrian M. Senderowicz, Suresh Bobba, Anas Younes, Andre Goy, Ian W. Flinn, Michael B. Maris, Jeffrey G. Supko, Kristie A. Blum
CONSORT diagram of patient disposition throughout study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e50340fb0c681ba5dcfe11908415005
https://doi.org/10.1158/2767-9764.22545008.v1
https://doi.org/10.1158/2767-9764.22545008.v1
Autor:
Owen A. O'Connor, Yaping Shou, Kathleen Roberge, Anca Milea, Eric L. Sievers, Robert A. Uger, Penka S. Petrova, Tina Catalano, Lisa D.S. Johnson, Oleg E. Akilov, Christiane Querfeld, Kerry J. Savage, Jasmine Zain, Matthew G. Mei, Steven M. Horwitz, James M. Foran, Anjali S. Advani, Mary-Elizabeth M. Percival, Diego Villa, Mark D. Minden, Ahmed Sawas, Ian W. Flinn, Robert W. Chen, Alexander M. Lesokhin, Michael B. Maris, Stephen M. Ansell
Study Schema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::281c50bb0e69ede50363e21f4afa6737
https://doi.org/10.1158/1078-0432.22482851.v1
https://doi.org/10.1158/1078-0432.22482851.v1
Autor:
Owen A. O'Connor, Yaping Shou, Kathleen Roberge, Anca Milea, Eric L. Sievers, Robert A. Uger, Penka S. Petrova, Tina Catalano, Lisa D.S. Johnson, Oleg E. Akilov, Christiane Querfeld, Kerry J. Savage, Jasmine Zain, Matthew G. Mei, Steven M. Horwitz, James M. Foran, Anjali S. Advani, Mary-Elizabeth M. Percival, Diego Villa, Mark D. Minden, Ahmed Sawas, Ian W. Flinn, Robert W. Chen, Alexander M. Lesokhin, Michael B. Maris, Stephen M. Ansell
Purpose:TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor activity by blocking the CD47 “don't eat me” signal. This first-in-human phase I study (NCT02663518) evaluated the safety and activity of TTI-621 in relapse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6229d70998f979096284ba3849db926
https://doi.org/10.1158/1078-0432.c.6531017
https://doi.org/10.1158/1078-0432.c.6531017